Standard BioTools (LAB) announced that the Precision Health Research, Singapore, PRECISE-SG100K, selected the SomaScan 11K Assay to run 100,000 plasma samples from the PRECISE-SG100K biobank following a comprehensive evaluation of competitive proteomics offerings. The combination of unmatched proteome coverage, superior reproducibility and high-quality service offering positioned SomaScan as the platform of choice, delivering the greatest overall value to this landmark initiative.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LAB:
- Standard BioTools Approves Stock Awards for Executives
- Standard BioTools Sells Subsidiaries to Illumina
- U.S. strikes Iran nuclear sites, Novo terminates Hims & Hers deal: Morning Buzz
- Standard BioTools to sell SomaLogic to Illumina for $350M upfront payment
- Illumina to acquire SomaLogic for $350M in cash